Patents Assigned to Neuren Pharmaceuticals Limited
-
Patent number: 11866406Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.Type: GrantFiled: June 23, 2022Date of Patent: January 9, 2024Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Clive Blower, Mathew Peterson, James Murray Shaw, James Anthony Bonnar, Etienne David Frank Philippe Moniotte, Martin Bernard Catherine Bousmanne, Cecilia Betti, Karel Willy Luc Decroos, Mimoun Ayoub
-
Patent number: 11370755Abstract: This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.Type: GrantFiled: June 14, 2021Date of Patent: June 28, 2022Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Clive Blower, Mathew Peterson, James Murray Shaw, James Anthony Bonnar, Etienne David Frank Philippe Moniotte, Martin Bernard Catherine Bousmanne, Cecilia Betti, Karel Willy Luc Decroos, Mimoun Ayoub
-
Patent number: 11197856Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autistic Disorder or Autism, as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: GrantFiled: January 22, 2020Date of Patent: December 14, 2021Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Cogram
-
Patent number: 10548892Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: GrantFiled: January 12, 2018Date of Patent: February 4, 2020Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
-
Publication number: 20180140601Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Applicant: Neuren Pharmaceuticals LimitedInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
-
Patent number: 9867823Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: GrantFiled: January 22, 2016Date of Patent: January 16, 2018Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
-
Publication number: 20170020869Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: ApplicationFiled: January 22, 2016Publication date: January 26, 2017Applicant: Neuren Pharmaceuticals LimitedInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
-
Patent number: 9212204Abstract: This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.Type: GrantFiled: January 26, 2015Date of Patent: December 15, 2015Assignee: Neuren Pharmaceuticals LimitedInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape
-
Publication number: 20150258091Abstract: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat symptoms of cognitive impairment associated with developmental disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.Type: ApplicationFiled: May 29, 2015Publication date: September 17, 2015Applicant: Neuren Pharmaceuticals LimitedInventors: Michael John Bickerdike, Jian Guan
-
Publication number: 20150197543Abstract: This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.Type: ApplicationFiled: January 26, 2015Publication date: July 16, 2015Applicant: Neuren Pharmaceuticals LimitedInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape
-
Publication number: 20140309230Abstract: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.Type: ApplicationFiled: June 25, 2014Publication date: October 16, 2014Applicant: Neuren Pharmaceuticals LimitedInventors: Michael John Bickerdike, Jian Guan
-
Patent number: 8791117Abstract: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.Type: GrantFiled: March 8, 2011Date of Patent: July 29, 2014Assignee: Neuren Pharmaceuticals LimitedInventors: Michael John Bickerdike, Jian Guan
-
Patent number: 8138304Abstract: Neural regeneration peptide consisting of a sequence comprised in the sequence of REGRRAAPGRAGG(SEQ ID NO:1).Type: GrantFiled: May 5, 2006Date of Patent: March 20, 2012Assignee: Neuren Pharmaceuticals LimitedInventors: Frank Sieg, Margaret Anne Brimble, Victoria Justine Muir
-
Patent number: 8067425Abstract: Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterized by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: GrantFiled: August 31, 2004Date of Patent: November 29, 2011Assignee: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Jian Guan, Frank Sieg
-
Publication number: 20110098228Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: April 6, 2010Publication date: April 28, 2011Applicant: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Publication number: 20110052528Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: ApplicationFiled: December 14, 2007Publication date: March 3, 2011Applicant: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble
-
Patent number: 7863304Abstract: Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.Type: GrantFiled: November 20, 2007Date of Patent: January 4, 2011Assignee: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Paul William Richard Harris, Frank Sieg
-
Publication number: 20100130410Abstract: Embodiments of this invention include novel peptides that can promote survival of neurons and other cell types. Other embodiments of this invention include the methods for the use of peptides to promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation, neuronal survival and/or trophoblast proliferation, trophoblast migration and trophoblase survival. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly or indirectly via a replicable vehicle. NRP compounds can be formulated into pharmaceutically acceptable dosage forms for therapeutic use. Kits containing pre-determined doses of an NRP can be used to conveniently store, prepare and administer an NRP to a subject in need thereof.Type: ApplicationFiled: May 5, 2006Publication date: May 27, 2010Applicant: Neuren Pharmaceuticals LimitedInventors: Frank Sieg, Margaret Anne Brimble, Victoria Justine Muir
-
Patent number: 7714020Abstract: Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.Type: GrantFiled: April 4, 2006Date of Patent: May 11, 2010Assignee: Neuren Pharmaceuticals LimitedInventors: Peter David Gluckman, Margaret Anne Brimble, Douglas Wilson, Frank Casper Tortella, Anthony Joseph Williams, Xi-Chun May Lu, Jed A. Hartings, Divina Gryder
-
Patent number: 7605177Abstract: This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.Type: GrantFiled: December 20, 2005Date of Patent: October 20, 2009Assignee: Neuren Pharmaceuticals LimitedInventors: Peter David Gluckman, Gregory Brian Thomas, Jian Guan, Michael Dragunow, Ashmit Kumar Anand, Frank Sieg, Margaret Anne Brimble